Search Results
176 results
Your search is now limited to «Biomarkers» expert search.
Right now, when we hear the term ‘AD,’ for example, even the experts don’t know whether this is someone with dementia or someone who tests positive for AD biomarkers,” he said.
More from Alzheimer's Research & Therapy:
Business Wire 03/22/2019 11:33
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Eisai neurodegenerative disease research studies.
More from Business Wire:
PR Newswire 03/22/2019 08:30
TOKYO, March 22, 2019 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been...
More from PR Newswire:
InsuranceNewsNet 03/21/2019 00:28
Participants at the conference agree that to expedite drug development efforts, we also must work concurrently to increase development in Alzheimer's biomarkers, which will improve rates of timely and accurate detection and diagnosis globally and speed adoption of innovative treatments.
More from InsuranceNewsNet:
FeedNavigator 03/19/2019 12:56
J Alzheimers Dis. 2019 Mar 11. doi: 10.3233/JAD-181252. [Epub ahead of print]
More from FeedNavigator: 03/19/2019 11:13
Further study is needed comparing protein biomarkers in the eye with more in-depth neurological testing," he concludes.
More from 03/19/2019 10:17
Low levels of amyloid-beta and tau proteins, biomarkers of Alzheimer's disease, in eye fluid were significantly associated with low cognitive scores, according to a new study.
More from 03/19/2019 06:46
The research published in the Journal of Alzheimer's Disease shows that these protein biomarkers of Alzheimer's disease (AD) in the eye is the potential source of cost-effective and accessible test to predict future disease risk.
More from
GlobeNewswire 03/15/2019 07:30
TORONTO and CAMBRIDGE, Mass., March 15, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2018.
More from GlobeNewswire: 03/14/2019 22:59
(Natural News) A study published in the journal Alzheimer’s & Dementia revealed that physical exercise can improve cognitive function and reduce the severity of the symptoms of Alzheimer’s disease. The researchers looked at the effects of physical activity in people with early-onset autosomal dominant Alzheimer’s disease. Early-onset autosomal dominant Alzheimer’s disease is a rare form...
More from
Bio-Medicine.Org 03/14/2019 06:32
MONTREAL (PRWEB) March 14, 2019 The eVox® System is a medical device that enables primary and specialty care physicians to assess brain function in-office and use the results to aid in making a clinical diagnosis. Marinela Gombosev, Chief Executive Officer at Evoke Neuroscience stat...
More from Bio-Medicine.Org:
Fight Aging! 03/12/2019 06:11
You might recall that researchers recently connected poor sleep with raised levels of tau in the brain. Sleep is needed to clear out tau, the amount of which rises during the active use of the brain while waking. Altered forms of tau protein can aggregate in the aging brain to form the neurofibrillary tangles that occur in later stages of Alzheimer's disease, and this might explain some of the known correlation between sleep disruption and neurodegeneration. The study here provides more data on this correlation, linking higher levels of tau with sleep apnea specifically, a common form of sleep disturbance. This is still a correlation in search of definitive proof of causation in humans, however, even if the recent animal study seems fairly
More from Fight Aging!:
Healio News 03/11/2019 14:00
Cholinesterase inhibitors, the most frequently used therapeutic agent to treat Alzheimer’s disease, appeared to help patients with primary progressive aphasia, or PPA, who have positive Alzheimer’s disease biomarkers, according to study findings.
More from Healio News:
This Viewpoint discusses the emerging role of the pre-caregiver in preclinical Alzheimer disease.
More from Archives of Neurology - Abstracts:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications